Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma
The aldose reductase inhibitor Fidarestat has been noted to have efficacy in treating a variety of tumors. To define its role in hepatocellular carcinoma (HCC), we induced a HCC xenograft model in mice, which were treated with different doses of Fidarestat. The amounts of natural killer (NK) cells a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Elsevier
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/eb3feba7ac6042e69abcc61b89e7756f |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|